Free Trial

This company has been marked as potentially delisted and may not be actively trading.

NASDAQ:CEMI

Chembio Diagnostics (CEMI) Stock Price, News & Analysis

Chembio Diagnostics logo

About Chembio Diagnostics Stock (NASDAQ:CEMI)

Advanced Chart

Key Stats

Today's Range
$0.45
$0.46
50-Day Range
$0.33
$0.46
52-Week Range
$0.19
$1.24
Volume
351,642 shs
Average Volume
661,416 shs
Market Capitalization
$16.71 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Chembio Diagnostics, Inc. engages in the developing, manufacturing, marketing, and licensing of rapid medical tests. It offers rapid point-of-care tests for infectious, tropical and fever, and respiratory diseases, handheld analyzers, and veterinary products. The firm distributes its products to hospitals and clinics, physician offices, clinical laboratories, public health organizations, government agencies, and consumers. The company was founded in 1985 and is headquartered in Medford, NY.

Receive CEMI Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Chembio Diagnostics and its competitors with MarketBeat's FREE daily newsletter.

CEMI Stock News Headlines

Quest Diagnostics Inc DGX
Warning: Massive IPO Predicted for May 14?
The #1 venture capitalist in America predicts that the biggest IPO in history will take place on Wednesday, May 14. And as Fortune has written, this IPO is “larger than any IPO valuation in history”…
See More Headlines

CEMI Stock Analysis - Frequently Asked Questions

Chembio Diagnostics, Inc. (NASDAQ:CEMI) posted its quarterly earnings results on Thursday, November, 4th. The company reported ($0.24) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.19) by $0.05. The firm had revenue of $12.06 million for the quarter. Chembio Diagnostics had a negative trailing twelve-month return on equity of 113.57% and a negative net margin of 47.03%.

Based on aggregate information from My MarketBeat watchlists, some other companies that Chembio Diagnostics investors own include Prospect Capital (PSEC), Calumet Specialty Products Partners (CLMT), Two Harbors Investment (TWO), NovoCure (NVCR), BlackRock Capital Investment (BKCC), Viper Energy (VNOM) and Summit Midstream Partners (SMLP).

Company Calendar

Last Earnings
11/04/2021
Today
5/12/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:CEMI
Employees
337
Year Founded
N/A

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$-23,290,000.00
Pretax Margin
-46.96%

Debt

Sales & Book Value

Annual Sales
$48.34 million
Price / Cash Flow
N/A
Book Value
$0.48 per share
Price / Book
0.95

Miscellaneous

Free Float
35,514,000
Market Cap
$16.71 million
Optionable
Not Optionable
Beta
1.85

Social Links

5G Stocks: The Path Forward is Profitable Cover

Enter your email address and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise.

Get This Free Report

This page (NASDAQ:CEMI) was last updated on 5/12/2025 by MarketBeat.com Staff
From Our Partners